Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Drugs retention" patented technology

High drug:lipid formulations of liposomal-antineoplastic agents

A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.
Owner:ELAN PHARM INC

Remote loading of sparingly water-soluble drugs into liposomes

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg / mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.
Owner:ZONEONE PHARMA

Coating system and method for drug elution management

ActiveUS20110086081A1Block mobilizationPromote retention of drugBiocidePeptide/protein ingredientsCoating systemPharmaceutical drug
The teachings are directed to a medical device having a drug-retaining coating that at least substantially delays the initial elution of a drug for a time effective at forming a functional endothelium over a surface of the medical device.
Owner:ALTAI MEDICAL TECH

Remote loading of sparingly water-soluble drugs into liposomes

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg / mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.
Owner:ZONEONE PHARMA

Liposome compositions for improved drugretention

The invention describes a liposome composition for enhanced retention of a quinolone compound, and in particular of a fluoroquinolone compound. Entrapped in the liposomes is a polyanionic polymer effective to form a complex with the fluoroquinolone. A method of preparing the liposomes which includes a process for removal of unentrapped polyanionic polymer is also described.
Owner:ALZA CORP

Medical device loaded with formulation for targeted delivery of biologically active material/s and method of manufacture thereof

InactiveUS20110274732A1High and nearly complete drug availabilityEasy to keepBiocideStentsPercent Diameter StenosisDrug release
The present invention relates to targeted drug delivery of a drug or therapeutic agent through medical devices coated with formulations comprising of therapeutic agent. The coating on medical devices comprises of therapeutic agent(s), affinity vehicle(s) and additives for targeted drug delivery of biologically active material(s). The invention provides a method of manufacturing the formulation, method of coating the medical devices with such formulations to achieve controlled delivery of optimum drug dose at the target site within the body, desirable drug retention on the medical devices in vivo and in vitro and desirable drug release at the target tissue in-vivo. The invention this provides a mechanism to enhance the bioavailability of the therapeutic agent at the target tissue in the treatment of restenosis thereby reduces the actual dose of the therapeutic agent and provides a very thin layer of coating on the surface of the medical device.
Owner:MERIL LIFE SCI PVT

Liposomal Formulations of Anthracycline Agents and Cytidine Analogs

Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Owner:CELATOR PHARMA INC

Remote loading of sparingly water-soluble drugs into liposomes

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg / mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.
Owner:CELATOR PHARMA INC

Immunosupportive drug sparing diet

The present invention is directed to immunosupportive, drug sparing diets and methods of using these diets. The compositions and methods disclosed herein increase the bioavailability of pharmaceutical compositions metabolized by the gut P450 isozymes.
Owner:RICE UNIV +1

Remote loading of sparingly water-soluble drugs into lipid vesicles

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg / mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading is capability retained. The process is scalable and the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and predictable drug retention when the liposome encapsulated drug is administered in patients.
Owner:CELATOR PHARMA INC

Remote loading of sparingly water-soluble drugs into liposomes

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg / mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.
Owner:ZONEONE PHARMA

Method for preparing coupled article of polyasparamide derivant and adriablastina, and uses thereof

The invention belongs to the biomedical technical field, and in particular relates to a synthesis of targeting macromolecular drug carriers and a synthesis of macromolecular pro-drug after the pro-drug is coupled with anti-cancer drug adriamycin. The carrier relates to a derivative of alpha and beta-polymer-(2-hydroxyethyl)-L-asparagine, modifies targeting group galactosyl and active group succinyl acyl on hydroxy group, and is a safe drug carrier with hepar targeting. The macromolecular pro-drug which is coupled with anti-cancer drug adriamycin reserves the antineoplastic function of adriamycin, lowers the toxic and side effect of adriamycin to bodies, and can be developed into one adriamycin pro-drug with hepar targeting.
Owner:合肥硕健医药科技有限公司

Negative-pressure transdermal drug delivery device

The invention provides a negative-pressure transdermal drug delivery device and aims to solve the problems that a conventional transdermal drug delivery device injures skin in the use process and is low in transdermal drug delivery curative effect. The technical key points are that a composite drug-loaded dressing containing a drug is loaded into the negative-pressure transdermal drug delivery device, a meshy elastic member fixed at the edge of the inner wall is arranged in the position, in contact with the skin, of the negative-pressure transdermal drug delivery device, and a semi-circular member allowing air to pass is arranged in the internal middle of the negative-pressure transdermal drug delivery device. After negative pressure is pumped into the negative-pressure transdermal drug delivery device, the surface area of the skin per unit area is increased, the skin tissue space is enlarged, and further, the drug transdermal impedance is reduced. Along with increase of the negative pressure, the meshy elastic member and the semi-circular member in the negative-pressure transdermal drug delivery device limits swelling of the skin and tissues, a reversed pushing action force is formed on the skin in negative pressure due to action of resistance, so that the drug can be easily loaded into the skin and enters a human body through the space-enlarged skin and tissues, and after relief of the negative pressure, the human body skin tissues recover while the drug remains in the human body.
Owner:柴雪青

Liposomes with improved drug retention for treatment of cancer

The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.
Owner:BRITISH COLUMBIA CANCER AGENCY BRANCH

Bare metal stent with drug eluting reservoirs having improved drug retention

Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions from a stent having reservoirs so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue. Features may be incorporated into the walls and bases of these reservoirs to improve securement of the drug construct.
Owner:CARDINAL HEALTH SWITZERLAND 515 GMBH

Liposomal formulations of anthracycline agents and cytidine analogs

Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Owner:CELATOR PHARMA INC

Pharmaceutical preparation for rectal administration

A pharmaceutical preparation for rectal administration by which a drug is retained in the affected region or the lower region of the rectum, where the drug is sustained-released is disclosed. The present invention is a pharmaceutical preparation for rectal administration comprising a coated drug-supported particle dispersed in a base, wherein the coated drug-supported particle is what a drug-supported porous microparticulate carrier is coated with a water-soluble polymer having a certain viscosity.
Owner:SATO PHARMA

Drug retaining surface features in an implantable medical device

An implantable component of a medical device, comprising a polymeric surface. The component includes one or more macro-surface features at the polymeric surface having a configuration that, following application of a liquid drug to the surface retains a quantity of the liquid drug adjacent the surface.
Owner:COCHLEAR LIMITED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products